Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Obesity, Overweight
In brief
This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.
Key facts
- Study ID
- NCT07220642
- Run by
- Novo Nordisk A/S
- People needed
- 300
- Starts
- 2025-11-05
- Expected to finish
- 2027-06-29
- Last updated by the study team
- 2026-08-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
- Female or male (sex at birth)
- Age 18 years or above at the time of signing the informed consent
- History of at least one self-reported unsuccessful dietary effort to lose body weight (a*)
- Body mass index (BMI) greater than or equal to >= 30.0 kilogram per square meter (kg/m\^2), or BMI greater than or equal to >= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease (a*)
You may not qualify if…
- History of type 1 or type 2 diabetes (a*)
- Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening (a*)
- Previous dosing of marketed or non-marketed amylin-based compounds (a*) (a*) - As declared by the participant, reported in the medical records or at the investigator's discretion.
Where it is running
- Diablo Clinical Research, Inc. — Walnut Creek, California, United States
- Univ of Colorado at Denver — Aurora, Colorado, United States
- Florida Inst For Clin Res LLC — Orlando, Florida, United States
- Oviedo Medical Research, LLC — Oviedo, Florida, United States
- Walgreens - Store 11760 — Oak Park, Illinois, United States
- Midwest Inst For Clin Res — Indianapolis, Indiana, United States
- StudyMetrix Research LLC — City of Saint Peters, Missouri, United States
- PharmQuest Life Sciences LLC — Greensboro, North Carolina, United States
- Selma Medical Associates — Winchester, Virginia, United States
- CIPREC Pueyrredon — Buenos Aires, Argentina
- CEDIC Centro de Investigación Clínica — CABA, Argentina
- Sydney Cardiometabolic Centre — Liverpool, New South Wales, Australia
- Hunter Diabetes Centre — Merewether, New South Wales, Australia
- G.A. Research Associates Ltd. — Moncton, New Brunswick, Canada
- Nova Scotia Hlth Halifax — Halifax, Nova Scotia, Canada
- Hamilton Medical Research Group — Hamilton, Ontario, Canada
- Wharton Medical Clinic Clinical Trials (Hamilton) — Hamilton, Ontario, Canada
- Milestone Research — London, Ontario, Canada
- Centricity Research Oshawa — Oshawa, Ontario, Canada
- Centricity Research Toronto — Toronto, Ontario, Canada
- Centricity Research Mirabel — Mirabel, Quebec, Canada
- Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec — Saint-Herblain, France
- Centre de Recherche Clinique Portes Du Sud — Vénissieux, France
- InnoDiab Forschung GmbH — Essen, Germany
- Wendisch - Dahl Hamburg - DZHW — Hamburg, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.